Literature DB >> 23711578

Relationship between left atrial tissue structural remodelling detected using late gadolinium enhancement MRI and left ventricular hypertrophy in patients with atrial fibrillation.

Mehmet Akkaya1, Koji Higuchi, Matthias Koopmann, Nathan Burgon, Ercan Erdogan, Kavitha Damal, Eugene Kholmovski, Chris McGann, Nassir F Marrouche.   

Abstract

AIMS: Therapeutic effectiveness of ablation of atrial fibrillation (AF) is related to cardiovascular comorbidities. We studied the relationship between left ventricular hypertrophy (LVH) and left atrial tissue structural remodelling (LA-SRM), in patients presenting for AF ablation. METHODS AND
RESULTS: We identified 404 AF patients who received a late gadolinium enhancement magnetic resonance imaging (LGE-MRI) prior to catheter ablation. Left ventricular hypertrophy was defined as LV mass index >116 g/m(2) in men and >104 g/m(2) in women. One hundred and twenty-two patients were classified as the LVH group and 282 as the non-LVH group. We stratified patients into four stages based on their degree of LA-SRM (minimal, <5% fibrosis; mild, >5-20%; moderate, >20-35%; and extensive, >35%). All patients underwent catheter ablation with pulmonary vein isolation and posterior wall and septal debulking. The procedural outcome was monitored over a 1-year follow-up period. The mean LA-SRM was significantly higher in patients with LVH (19.4 ± 13.2%) than in non-LVH patients (15.3 ± 9.8%; P< 0.01). Patients with LVH generally had extensive LA-SRM (moderate and extensive stages; 38.5% of LVH group) as compared with non-LVH patients (23.1% of non-LVH group; P < 0.01). A Cox regression analysis showed that patients with LVH also had significantly higher AF recurrence rates than non-LVH patients (43.2 vs. 28%; P = 0.008) during the 1-year follow-up period post-ablation.
CONCLUSION: Patients with LVH tend to have a significantly greater degree of LA-SRM, when compared with patients without LVH. Moreover, LA-SRM is a predictor for procedural success in patients undergoing AF ablation procedure.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Left ventricular hypertrophy; MRI; Structural remodelling

Mesh:

Substances:

Year:  2013        PMID: 23711578     DOI: 10.1093/europace/eut147

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  13 in total

1.  Compressed sensing for rapid late gadolinium enhanced imaging of the left atrium: A preliminary study.

Authors:  Srikant Kamesh Iyer; Tolga Tasdizen; Nathan Burgon; Eugene Kholmovski; Nassir Marrouche; Ganesh Adluru; Edward DiBella
Journal:  Magn Reson Imaging       Date:  2016-03-08       Impact factor: 2.546

2.  Possible involvement of TGF-β/periostin in fibrosis of right atrial appendages in patients with atrial fibrillation.

Authors:  Han Wu; Jun Xie; Guan-Nan Li; Qin-Hua Chen; Ran Li; Xin-Lin Zhang; Li-Na Kang; Biao Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation.

Authors:  Song-Nan Li; Lu Wang; Jian-Zeng Dong; Rong-Hui Yu; De-Yong Long; Ri-Bo Tang; Cai-Hua Sang; Chen-Xi Jiang; Nian Liu; Rong Bai; Xin Du; Chang-Sheng Ma
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

4.  Topographic variability of the left atrium and pulmonary veins assessed by 3D-CT predicts the recurrence of atrial fibrillation after catheter ablation.

Authors:  Kunihiko Kiuchi; Akihiro Yoshida; Asumi Takei; Koji Fukuzawa; Mitsuaki Itoh; Kimitake Imamura; Ryudo Fujiwara; Atsushi Suzuki; Tomoyuki Nakanishi; Soichiro Yamashita; Ken-Ichi Hirata; Gaku Kanda; Katsunori Okajima; Akira Shimane; Shinichiro Yamada; Yasuyo Taniguchi; Yoshinori Yasaka; Hiroya Kawai
Journal:  J Arrhythm       Date:  2015-04-25

5.  Relationship between QRS duration and incident atrial fibrillation.

Authors:  Stefanie Aeschbacher; Wesley T O'Neal; Philipp Krisai; Laura Loehr; Lin Y Chen; Alvaro Alonso; Elsayed Z Soliman; David Conen
Journal:  Int J Cardiol       Date:  2018-09-01       Impact factor: 4.164

6.  Clinical predictors of cardiac magnetic resonance late gadolinium enhancement in patients with atrial fibrillation.

Authors:  Jonathan Chrispin; Esra Gucuk Ipek; Mohammadali Habibi; Eunice Yang; David Spragg; Joseph E Marine; Hiroshi Ashikaga; John Rickard; Ronald D Berger; Stefan L Zimmerman; Hugh Calkins; Saman Nazarian
Journal:  Europace       Date:  2017-03-01       Impact factor: 5.214

7.  Visualization of pulmonary vein-left atrium lesions using delayed-enhancement magnetic resonance imaging after cryothermal balloon catheter ablation: A case report.

Authors:  Tsuyoshi Mishima; Koji Miyamoto; Yoshiaki Morita; Takashi Noda; Takeshi Aiba; Kengo Kusano
Journal:  HeartRhythm Case Rep       Date:  2015-08-28

8.  Motion-corrected 3D whole-heart water-fat high-resolution late gadolinium enhancement cardiovascular magnetic resonance imaging.

Authors:  Camila Munoz; Aurelien Bustin; Radhouene Neji; Karl P Kunze; Christoph Forman; Michaela Schmidt; Reza Hajhosseiny; Pier-Giorgio Masci; Martin Zeilinger; Wolfgang Wuest; René M Botnar; Claudia Prieto
Journal:  J Cardiovasc Magn Reson       Date:  2020-07-20       Impact factor: 5.364

9.  Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation.

Authors:  Archontis Giannakidis; Eva Nyktari; Jennifer Keegan; Iain Pierce; Irina Suman Horduna; Shouvik Haldar; Dudley J Pennell; Raad Mohiaddin; Tom Wong; David N Firmin
Journal:  Biomed Eng Online       Date:  2015-10-07       Impact factor: 2.819

10.  Prognostic and functional implications of left atrial late gadolinium enhancement cardiovascular magnetic resonance.

Authors:  Michael Quail; Karl Grunseich; Lauren A Baldassarre; Hamid Mojibian; Mark A Marieb; Daniel Cornfeld; Aaron Soufer; Albert J Sinusas; Dana C Peters
Journal:  J Cardiovasc Magn Reson       Date:  2019-01-03       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.